Abstract
STAG2 encodes a cohesin component and is frequently mutated in myeloid neo-plasms, showing highly significant comutation patterns with other drivers, including RUNX1. However, the molecular basis of cohesin-mutated leukemogenesis remains poorly understood. Here we show a critical role of an interplay between STAG2 and RUNX1 in the regulation of enhancer– promoter looping and transcription in hematopoiesis. Combined loss of STAG2 and RUNX1, which colocalize at enhancer-rich, CTCF-deficient sites, synergistically attenuates enhancer–promoter loops, particularly at sites enriched for RNA polymerase II and Mediator, and deregulates gene expression, leading to myeloid-skewed expansion of hematopoietic stem/progenitor cells (HSPC) and myelodys-plastic syndromes (MDS) in mice. Attenuated enhancer–promoter loops in STAG2/RUNX1–deficient cells are associated with downregulation of genes with high basal transcriptional pausing, which are important for regulation of HSPCs. Downregulation of high-pausing genes is also confirmed in STAG2– cohesin-mutated primary leukemia samples. Our results highlight a unique STAG2–RUNX1 interplay in gene regulation and provide insights into cohesin-mutated leukemogenesis. SIGNIFICANCE: We demonstrate a critical role of an interplay between STAG2 and a master transcription factor of hematopoiesis, RUNX1, in MDS development, and further reveal their contribution to regulation of high-order chromatin structures, particularly enhancer–promoter looping, and the link between transcriptional pausing and selective gene dysregulation caused by cohesin deficiency.
Original language | English |
---|---|
Pages (from-to) | 836-853 |
Number of pages | 18 |
Journal | Cancer Discovery |
Volume | 10 |
Issue number | 6 |
DOIs | |
Publication status | Published - 2020 Jun |
Externally published | Yes |
ASJC Scopus subject areas
- Oncology
Access to Document
Other files and links
Fingerprint
Dive into the research topics of 'Combined Cohesin–RUNX1 deficiency synergistically perturbs chromatin looping and causes myelodysplastic syndromes'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In: Cancer Discovery, Vol. 10, No. 6, 06.2020, p. 836-853.
Research output: Contribution to journal › Article › peer-review
}
TY - JOUR
T1 - Combined Cohesin–RUNX1 deficiency synergistically perturbs chromatin looping and causes myelodysplastic syndromes
AU - Ochi, Yotaro
AU - Kon, Ayana
AU - Sakata, Toyonori
AU - Nakagawa, Masahiro M.
AU - Nakazawa, Naotaka
AU - Kakuta, Masanori
AU - Kataoka, Keisuke
AU - Koseki, Haruhiko
AU - Nakayama, Manabu
AU - Morishita, Daisuke
AU - Tsuruyama, Tatsuaki
AU - Saiki, Ryunosuke
AU - Yoda, Akinori
AU - Okuda, Rurika
AU - Yoshizato, Tetsuichi
AU - Yoshida, Kenichi
AU - Shiozawa, Yusuke
AU - Nannya, Yasuhito
AU - Kotani, Shinichi
AU - Kogure, Yasunori
AU - Kakiuchi, Nobuyuki
AU - Nishimura, Tomomi
AU - Makishima, Hideki
AU - Malcovati, Luca
AU - Yokoyama, Akihiko
AU - Takeuchi, Kengo
AU - Sugihara, Eiji
AU - Sato, Taka Aki
AU - Sanada, Masashi
AU - Takaori-Kondo, Akifumi
AU - Cazzola, Mario
AU - Kengaku, Mineko
AU - Miyano, Satoru
AU - Shirahige, Katsuhiko
AU - Suzuki, Hiroshi I.
AU - Ogawa, Seishi
N1 - Funding Information: We thank Satoko Yabuta, Ai Takatsu, Akiko Ozaki, Atsuko Ryu, Maki Nakamura, Takeshi Shirahari (Department of Pathology and Tumor Biology, Kyoto University, Japan), and Satoko Baba (Pathol-ogy Project for Molecular Targets, Cancer Institute, Japanese Foundation for Cancer Research) for technical assistance; Dr. Kazuko Miyazaki and Dr. Masaki Miyazaki (Department of Immunology, Institute for Frontier Life and Medical Sciences, Kyoto University) for technical advice on ATAC-seq and ChIP-seq experiments; Dr. Shuhei Asada and Dr. Toshio Kitamura (Division of Cellular Therapy, The Institute of Medical Science, University of Tokyo, Tokyo, Japan) for providing vectors; the Center for Anatomical, Pathological and Forensic Medical Research, Kyoto University Graduate School of Medicine, for preparing microscope slide; and iLAC, Co., Ltd. for sequencing support. Super-resolution imaging was performed at the iCeMS Analysis Center, Institute for Integrated Cell-Material Sciences (iCeMS), Kyoto University Institute for Advanced Study (KUIAS), and we thank Dr. Takahiro Fujiwara for data analysis and Fumiyoshi Ishidate for technical assistance (iCeMS Analysis Center). The super-computing resource was provided by Human Genome Center, the Institute of Medical Science, the University of Tokyo. The results shown here are in part based upon data generated by The Cancer Genome Atlas Research Network: https://www.cancer.gov/tcga. This work was supported by Grant-in-Aid for Scientific Research (MEXT/JSPS KAKENHI JP26221308 and JP26253060, to S. Ogawa; JP17J05245, to Y. Ochi; JP18K16084, to A. Kon; JP19H03560, to A. Yoda), MEXT as “Priority Issue on Post-K computer” (Integrated Computational Life Science to Support Personalized and Preventive Medicine; hp180198, hp190179, to S. Ogawa and S. Miyano), Grants-in-Aid from the Japan Agency for Medical Research and Development (AMED; JP15cm0106056, JP19cm0106501, JP16ck0106073, JP19ck0106250, to S. Ogawa; JP19cm0106138, to A. Kon), Scientific Research on Innovative Areas (15H05909, 15H05912, to S. Ogawa and S. Miyano; JP15H05979, to K. Yoshida and A. Kon; 15H05976, to K. Shirahige; 19H04806, to A. Yoda), “Stem Cell Aging and Dis-ease” (14430052, to M. Sanada), JST CREST (JPMJCR18S5, to K. Shirahige), grants from Takeda Science Foundation (to S. Ogawa, H. Makishima, T. Yoshizato, and A. Kon), Naito Foundation (to A. Yoda), TERUMO LIFE SCIENCE FOUNDATION (to A. Yoda), Yasuda Medical Foundation (to A. Yoda), and JSPS Core-to-Core Program (to S. Ogawa). Studies conducted at Massachusetts Institute of Technology were supported by the United States Public Health Service Grant R01-GM034277 and R01-CA133404 (to P.A. Sharp) and P01-CA042063 (to T. Jacks) from the NIH and by the Koch Institute Support (core) grant P30-CA14051 from the National Cancer Insti-tute, and supported in part by an agreement between the Whitehead Institute for Biomedical Research and Novo Nordisk. Studies conducted at the University of Pavia and Fondazione IRCCS Policlinico San Matteo, Pavia, Italy, were supported by Associazione Italiana per la Ricerca sul Cancro (AIRC), Milan, Italy (Investigator Grant #20125, to L. Malcovati; AIRC 5 × 1000 project #21267, to M. Cazzola). Funding Information: We thank Satoko Yabuta, Ai Takatsu, Akiko Ozaki, Atsuko Ryu, Maki Nakamura, Takeshi Shirahari (Department of Pathology and Tumor Biology, Kyoto University, Japan), and Satoko Baba (Pathology Project for Molecular Targets, Cancer Institute, Japanese Foundation for Cancer Research) for technical assistance; Dr. Kazuko Miyazaki and Dr. Masaki Miyazaki (Department of Immunology, Institute for Frontier Life and Medical Sciences, Kyoto University) for technical advice on ATAC-seq and ChIP-seq experiments; Dr. Shuhei Asada and Dr. Toshio Kitamura (Division of Cellular Therapy, The Institute of Medical Science, University of Tokyo, Tokyo, Japan) for providing vectors; the Center for Anatomical, Pathological and Forensic Medical Research, Kyoto University Graduate School of Medicine, for preparing microscope slide; and iLAC, Co., Ltd. for sequencing support. Super-resolution imaging was performed at the iCeMS Analysis Center, Institute for Integrated Cell-Material Sciences (iCeMS), Kyoto University Institute for Advanced Study (KUIAS), and we thank Dr. Takahiro Fujiwara for data analysis and Fumiyoshi Ishidate for technical assistance (iCeMS Analysis Center). The super-computing resource was provided by Human Genome Center, the Institute of Medical Science, the University of Tokyo. The results shown here are in part based upon data generated by The Cancer Genome Atlas Research Network: https://www.cancer.gov/tcga. This work was supported by Grant-in-Aid for Scientific Research (MEXT/JSPS KAKENHI JP26221308 and JP26253060, to S. Ogawa; JP17J05245, to Y. Ochi; JP18K16084, to A. Kon; JP19H03560, to A. Yoda), MEXT as “Priority Issue on Post-K computer” (Integrated Computational Life Science to Support Personalized and Preventive Medicine; hp180198, hp190179, to S. Ogawa and S. Miyano), Grants-in-Aid from the Japan Agency for Medical Research and Development (AMED; JP15cm0106056, JP19cm0106501, JP16ck0106073, JP19ck0106250, to S. Ogawa; JP19cm0106138, to A. Kon), Scientific Research on Innovative Areas (15H05909, 15H05912, to S. Ogawa and S. Miyano; JP15H05979, to K. Yoshida and A. Kon; 15H05976, to K. Shirahige; 19H04806, to A. Yoda), “Stem Cell Aging and Disease” (14430052, to M. Sanada), JST CREST (JPMJCR18S5, to K. Shirahige), grants from Takeda Science Foundation (to S. Ogawa, H. Makishima, T. Yoshizato, and A. Kon), Naito Foundation (to A. Yoda), TERUMO LIFE SCIENCE FOUNDATION (to A. Yoda), Yasuda Medical Foundation (to A. Yoda), and JSPS Core-to-Core Program (to S. Ogawa). Studies conducted at Massachusetts Institute of Technology were supported by the United States Public Health Service Grant R01-GM034277 and R01-CA133404 (to P.A. Sharp) and P01-CA042063 (to T. Jacks) from the NIH and by the Koch Institute Support (core) grant P30-CA14051 from the National Cancer Institute, and supported in part by an agreement between the Whitehead Institute for Biomedical Research and Novo Nordisk. Studies conducted at the University of Pavia and Fondazione IRCCS Policlinico San Matteo, Pavia, Italy, were supported by Associazione Italiana per la Ricerca sul Cancro (AIRC), Milan, Italy (Investigator Grant #20125, to L. Malcovati; AIRC 5 × 1000 project #21267, to M. Cazzola). Publisher Copyright: © 2020 American Association for Cancer Research.
PY - 2020/6
Y1 - 2020/6
N2 - STAG2 encodes a cohesin component and is frequently mutated in myeloid neo-plasms, showing highly significant comutation patterns with other drivers, including RUNX1. However, the molecular basis of cohesin-mutated leukemogenesis remains poorly understood. Here we show a critical role of an interplay between STAG2 and RUNX1 in the regulation of enhancer– promoter looping and transcription in hematopoiesis. Combined loss of STAG2 and RUNX1, which colocalize at enhancer-rich, CTCF-deficient sites, synergistically attenuates enhancer–promoter loops, particularly at sites enriched for RNA polymerase II and Mediator, and deregulates gene expression, leading to myeloid-skewed expansion of hematopoietic stem/progenitor cells (HSPC) and myelodys-plastic syndromes (MDS) in mice. Attenuated enhancer–promoter loops in STAG2/RUNX1–deficient cells are associated with downregulation of genes with high basal transcriptional pausing, which are important for regulation of HSPCs. Downregulation of high-pausing genes is also confirmed in STAG2– cohesin-mutated primary leukemia samples. Our results highlight a unique STAG2–RUNX1 interplay in gene regulation and provide insights into cohesin-mutated leukemogenesis. SIGNIFICANCE: We demonstrate a critical role of an interplay between STAG2 and a master transcription factor of hematopoiesis, RUNX1, in MDS development, and further reveal their contribution to regulation of high-order chromatin structures, particularly enhancer–promoter looping, and the link between transcriptional pausing and selective gene dysregulation caused by cohesin deficiency.
AB - STAG2 encodes a cohesin component and is frequently mutated in myeloid neo-plasms, showing highly significant comutation patterns with other drivers, including RUNX1. However, the molecular basis of cohesin-mutated leukemogenesis remains poorly understood. Here we show a critical role of an interplay between STAG2 and RUNX1 in the regulation of enhancer– promoter looping and transcription in hematopoiesis. Combined loss of STAG2 and RUNX1, which colocalize at enhancer-rich, CTCF-deficient sites, synergistically attenuates enhancer–promoter loops, particularly at sites enriched for RNA polymerase II and Mediator, and deregulates gene expression, leading to myeloid-skewed expansion of hematopoietic stem/progenitor cells (HSPC) and myelodys-plastic syndromes (MDS) in mice. Attenuated enhancer–promoter loops in STAG2/RUNX1–deficient cells are associated with downregulation of genes with high basal transcriptional pausing, which are important for regulation of HSPCs. Downregulation of high-pausing genes is also confirmed in STAG2– cohesin-mutated primary leukemia samples. Our results highlight a unique STAG2–RUNX1 interplay in gene regulation and provide insights into cohesin-mutated leukemogenesis. SIGNIFICANCE: We demonstrate a critical role of an interplay between STAG2 and a master transcription factor of hematopoiesis, RUNX1, in MDS development, and further reveal their contribution to regulation of high-order chromatin structures, particularly enhancer–promoter looping, and the link between transcriptional pausing and selective gene dysregulation caused by cohesin deficiency.
UR - http://www.scopus.com/inward/record.url?scp=85085905162&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85085905162&partnerID=8YFLogxK
U2 - 10.1158/2159-8290.CD-19-0982
DO - 10.1158/2159-8290.CD-19-0982
M3 - Article
C2 - 32249213
AN - SCOPUS:85085905162
SN - 2159-8274
VL - 10
SP - 836
EP - 853
JO - Cancer Discovery
JF - Cancer Discovery
IS - 6
ER -